YKYoshihide Kii

Yoshihide Kii

*This is an algorithmically generated author record based on publicly available information.

Yoshihide Kii has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Tsugutaka Ito

    Safety Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, Japan

    3 shared publications
  • Isamu Nose

    Safety Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, Japan

    2 shared publications
  • Katsuyoshi Nakatsuji

    Safety Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, Japan

    2 shared publications
  • Masafumi Yabuuchi

    Safety Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, Japan

    2 shared publications
  • Michiaki Matsuda

    Pharmacokinetics and Physico-Chemical Property Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, Japan

    1 shared publication
  • Yasuyuki Mizuki

    1 shared publication

Latest Publications

  • Effects of antihistamines, ebastine and terfenadine, on electrocardiogram in conscious dogs and cats

    by Yoshihide Kii, Katsuyoshi Nakatsuji, Isamu Nose, Masafumi Yabuuchi, Michiaki Matsuda, Tsugutaka Ito

    The purpose of this study was to evaluate the effects of ebastine and terfenadine on the electrocardiogram of conscious dogs and cats. In dogs, terfenadine at oral doses of 30 mg/kg twice a day for 7 days prolonged the electrocardiographic QT interval and the corrected QT (QTc) interval on the seventh day, whereas the drug did not affect these parameters on the first day. Plasma concentrations of terfenadine and its active metabolite, fexofenadine, reached 306 and 8,541 ng/mL, respectively, on the seventh day. Ebastine at oral doses of 30 and 100 mg/kg once a day for 7 days was without effect on the QT and QTc intervals, whereas the drug slightly shortened the RR interval. On the seventh day following the dose of 100 mg/kg, plasma concentrations of ebastine and its active metabolite, carebastine, reached 36 and 1,939 ng/mL, respectively. In conscious cats, terfenadine at oral doses of 30 mg/kg twice a day for 7 days prolonged the QT and QTc intervals, QRS duration, JT and the corrected JT intervals. Unexpectedly, terfenadine induced ventricular tachyarrhythmia and premature beats. On the other hand, ebastine at oral doses of 100 mg/kg once a day for 7 days was without effect on the electrocardiographic parameters in cats. These results suggest that the electrocardiographic changes indicative of the proarrhythmic potential of terfenadine can be evaluated in conscious dogs and especially in conscious cats by repeated oral administration, and that ebastine does not induce such changes. 58:209–217, 2003.


  • Effects of 5-HT4 Receptor Agonists, Cisapride and Mosapride Citrate on Electrocardiogram in Anaesthetized Rats and Guinea-Pigs and Conscious Cats

    by Yoshihide Kii, Katsuyoshi Nakatsuji, Isamu Nose, Masafumi Yabuuchi, Yasuyuki Mizuki, Tsugutaka Ito

    The purpose of this study was to examine the arrhythmogenic potential of 5-HT4 receptor agonists, cisapride and mosapride citrate (mosapride) in vivo. In anaesthetized rats, cisapride at intravenous infusion of 10 and 30 mg/kg/hr for 1 hr prolonged the electrocardiographic RR and QT intervals, whereas at 3 mg/kg/hr, it prolonged the RR interval without affecting the QT interval. Mosapride at 30 mg/kg/hr for 1 hr slightly, but not significantly, prolonged the QT interval. In anaesthetized guinea-pigs, cisapride at intravenous infusion of 0.3, 1 and 3 mg/kg over 15 min. prolonged the RR interval (18-44%), QT interval (18-42%) and the corrected QT interval (QTc; 8-19%). Mosapride at 3, 10 and 30 mg/kg over 15 min. little affected the QTc although at 30 mg/kg, it slightly prolonged the RR and QT intervals. With repeated oral administrations of 30 mg/kg twice a day for 7 days, cisapride prolonged the QT interval (11-35%) and QTc (11-32%) at the 3rd and 7th days in conscious cats. In addition, cisapride depressed the ST segment in two out of five cats. Mosapride at 60 mg/kg twice a day for 7 days did not affect the QT interval or QTc in cats. The maximal plasma concentrations of mosapride and its main metabolite (a des-4-fluorobenzyl-mosapride) at the 7th day in cats were 9.4+/-2.8 microM and 2.5+/-0.3 microM , respectively, being 100 and 30-60 times higher than those in man given therapeutic doses (Sakashita et al. 1993a&b). These results indicate that mosapride has little arrhythmogenic potential.